Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Autoimmune Disorders

Free Subscription 10.08.2026 1 BMC Neurol 1 Brain 1 Diabetes Res Clin Pract 1 Intern Med 3 J Nephrol 8 J Neuroimmunol 3 J Neurol 1 J Pediatr Endocrinol Metab 3 J Rheumatol 2 Kidney Int 9 Mult Scler 1 N Engl J Med 1 Nat Rev Neurol 1 Neurol Clin Pract 1 Neurology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Neurol

1. WU Y, Gu L, Liu J, Yang W, et al
   Anti-GLDN antibody-associated CIDP (nodopathy): transient IVIg response and B-cell depletion remission.
   BMC Neurol. 2026;26:490.
   PubMed         Abstract available
   
   

   
   Brain

2. DA SILVA MTT, Araujo AQC
   HTLV-1-associated myelopathy as a translational model of progressive neurodegeneration.
   Brain. 2026;149:2592-2603.
   PubMed         Abstract available
   
   

   
   Diabetes Res Clin Pract

3. VITA F, Zampetti S, Latino A, Pieralice S, et al
   Improved glycemic control with the MiniMed 780G system in latent autoimmune diabetes and type 1 diabetes: a real-world observational study.
   Diabetes Res Clin Pract. 2026 Aug 6:113470. doi: 10.1016/j.diabres.2026.113470.
   PubMed         Abstract available
   
   

   
   Intern Med

4. MATSUSHITA Y, Umeda M, Kurohama H, Origuchi T, et al
   Improvement of Lymphedema in IgG4-Related Disease with Oral Glucocorticoid Therapy.
   Intern Med. 2026;65:2154-2159.
   PubMed         Abstract available
   
   

   
   J Nephrol

5. FETOUH MG, Sabry A, Fouda MA, Abdulrahim M, et al
   Repeat kidney biopsy unmasks the transition from active inflammation to irreversible damage in lupus nephritis: longitudinal outcomes from a single-center cohort in Egypt.
   J Nephrol. 2026 Aug 6:aajag097. doi: 10.1093.
   PubMed         Abstract available
   
   
6. PAUL SP, Roy S, Matthai SM, Gopinathan V, et al
   Histopathologic and clinical spectrum of IgA nephropathy coexisting with other glomerulopathies; addressing the diagnostic challenges. Experience from a tertiary care center.
   J Nephrol. 2026 Aug 5:aajag067. doi: 10.1093.
   PubMed         Abstract available
   
   
7. JING S, Yang X, Li S, Dong L, et al
   Predicting the risk of lupus nephritis based on a nomogram in patients with childhood-onset systemic lupus erythematosus.
   J Nephrol. 2026 Aug 4:aajaf003. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Neuroimmunol

8. FAZAZI MR, Champagne-Jorgensen K, Islam T, Tweed K, et al
   Epstein-Barr virus and multiple sclerosis: Mechanisms, therapeutic implications, and emerging interventions.
   J Neuroimmunol. 2026;420:579043.
   PubMed         Abstract available
   
   
9. MESSINA C
   Beyond muscle weakness: Expanding the therapeutic horizon of thymectomy in myasthenia gravis.
   J Neuroimmunol. 2026;420:579041.
   PubMed        
   
   
10. LI Y, Zhang M, Liu Z
    Identification of PTGS2 as a genetically supported protective biomarker and potential therapeutic target in myasthenia gravis.
    J Neuroimmunol. 2026;420:579044.
    PubMed         Abstract available
    
    
11. TALBOT J, Hojsgaard Chow H, Romme Christensen J, Ratzer R, et al
    Chitinase-1 in cerebrospinal fluid and white matter injury in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2026;420:579034.
    PubMed         Abstract available
    
    
12. INAN B
    Comment on "Longitudinal MuSK antibody levels may correlate with disease severity in MuSK myasthenia gravis".
    J Neuroimmunol. 2026;420:579047.
    PubMed        
    
    
13. YASUDA M, Uzawa A
    Response to the comment on "Longitudinal MuSK antibody levels may correlate with disease severity in MuSK myasthenia gravis".
    J Neuroimmunol. 2026;420:579052.
    PubMed        
    
    
14. HASEGAWA T, Ando T, Sekikawa H, Tsuda H, et al
    Intitiation of satralizumab during pregnancy for successful childbirth in neuromyelitis optica spectrum disorder: A case report and literature review.
    J Neuroimmunol. 2026;419:578997.
    PubMed         Abstract available
    
    
15. ZHUANG Q, Quan C, Zhangbao J, Gao M, et al
    Clinical characteristics of IgG4-related hypertrophic pachymeningitis with and without serum ANCA positivity.
    J Neuroimmunol. 2026;419:579007.
    PubMed         Abstract available
    
    

    
    J Neurol

16. CERDA-FUERTES N, Sankar S, Pless S, Stoessel M, et al
    Retinal layers prognosticate cognitive progression independent of relapse activity in multiple sclerosis.
    J Neurol. 2026;273:517.
    PubMed         Abstract available
    
    
17. SREDANOVIC M, Hentzen C, Adamec I, Chesnel C, et al
    Gastrointestinal symptoms and disorders in multiple sclerosis: a systematic review and meta-analysis.
    J Neurol. 2026;273:515.
    PubMed         Abstract available
    
    
18. RICIGLIANO VAG, Ciron J, Bourre B, Guennoc AM, et al
    French expert opinion on the long-term management of relapsing multiple sclerosis with cladribine tablets beyond year 4.
    J Neurol. 2026;273:507.
    PubMed         Abstract available
    
    

    
    J Pediatr Endocrinol Metab

19. AYDIN DB, Uruc B, Aydin E, Comlek FO, et al
    Larks vs. owls: exploring chronotype, glycaemic control, and quality of life in paediatric type 1 diabetes.
    J Pediatr Endocrinol Metab. 2026;39:749-755.
    PubMed         Abstract available
    
    

    
    J Rheumatol

20. VLEUGELS RA, Peeva E, Aggarwal R, Chu M, et al
    Long-term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase 2 Results from Double-blind and Open-Label Extension Studies.
    J Rheumatol. 2026 Aug 1:jrheum.2026-0146. doi: 10.3899/jrheum.2026-0146.
    PubMed         Abstract available
    
    
21. KIM Y, Guan H, Choi MY, Paudel M, et al
    Comparative Performance of SLECRISK and PREVENT for Cardiovascular Risk Prediction in Systemic Lupus Erythematosus.
    J Rheumatol. 2026 Aug 1:jrheum.2025-1318. doi: 10.3899/jrheum.2025-1318.
    PubMed         Abstract available
    
    
22. WELTEN A, Zhong S, Gilliland J, Miller M, et al
    The Ecological Relationship Between Food Access and Disease Activity in Canadian Children Newly Diagnosed With Juvenile Idiopathic Arthritis.
    J Rheumatol. 2026;53:899-904.
    PubMed         Abstract available
    
    

    
    Kidney Int

23. FLOEGE J
    Triple immunosuppressive therapy in active lupus nephritis: does one therapy really fit all?
    Kidney Int. 2026 Jul 29:S0085-2538(26)00544-2. doi: 10.1016/j.kint.2026.
    PubMed        
    
    
24. MEJIA-VILET JM, Ayoub I
    Front-loading response: why combination therapy should anchor initial lupus nephritis treatment.
    Kidney Int. 2026 Jul 29:S0085-2538(26)00543-0. doi: 10.1016/j.kint.2026.
    PubMed        
    
    

    
    Mult Scler

25. SOARES-DOS-REIS R, Silva-Pinto A
    Borrelia miyamotoi meningoradiculitis in multiple sclerosis patients treated with B-cell-depleting therapies.
    Mult Scler. 2026 Aug 4:13524585261473072. doi: 10.1177/13524585261473072.
    PubMed        
    
    
26. FREEDMAN DE, Oh J, Feinstein A
    Post-traumatic stress disorder in people with multiple sclerosis: A narrative review.
    Mult Scler. 2026 Aug 5:13524585261475088. doi: 10.1177/13524585261475088.
    PubMed         Abstract available
    
    
27. NICOLAS P, Beigneux Y, Guennoc AM, Destras G, et al
    Borrelia miyamotoi meningoradiculitis complicating ocrelizumab treatment for multiple sclerosis: A report of three cases.
    Mult Scler. 2026 Aug 4:13524585261473068. doi: 10.1177/13524585261473068.
    PubMed         Abstract available
    
    
28. BRITTAIN G, Long M, Buckley E, Becker C, et al
    Testing the construct validity of real-world digital mobility outcomes in multiple sclerosis.
    Mult Scler. 2026 Aug 2:13524585261464537. doi: 10.1177/13524585261464537.
    PubMed         Abstract available
    
    
29. NESBITT C, Sanfilippo P, Zhu C, Ozakbas S, et al
    Multiple sclerosis outcomes after cancer diagnosis in people with recorded chemotherapy exposure: A real-world MSBase study.
    Mult Scler. 2026 Aug 2:13524585261460658. doi: 10.1177/13524585261460658.
    PubMed         Abstract available
    
    
30. KARRENBAUER VD, Olsson T, Alfredsson L, Hedstrom AK, et al
    Shared etiology of late- and adult-onset multiple sclerosis.
    Mult Scler. 2026 Aug 5:13524585261472320. doi: 10.1177/13524585261472320.
    PubMed         Abstract available
    
    
31. ALBERGONI M, Preziosa P, Ritroso G, Tedone N, et al
    Vascular risk factors' impact on motor performance and sensorimotor network structural integrity in multiple sclerosis.
    Mult Scler. 2026 Aug 6:13524585261464469. doi: 10.1177/13524585261464469.
    PubMed         Abstract available
    
    
32. DRYZER MH, Nourbakhsh B, Keller J, Chib VS, et al
    Increased exertion variability is linked to disruptions in effort assessment in multiple sclerosis.
    Mult Scler. 2026 Aug 7:13524585261469807. doi: 10.1177/13524585261469807.
    PubMed         Abstract available
    
    
33. PIERRET C, Bouvier R, Kerbrat S, Leray E, et al
    Colorectal cancer screening in individuals with multiple sclerosis: A mixed-methods study.
    Mult Scler. 2026 Aug 7:13524585261465197. doi: 10.1177/13524585261465197.
    PubMed         Abstract available
    
    

    
    N Engl J Med

34. KAYASHIMA A, Horibe M
    Type 1 Autoimmune Pancreatitis.
    N Engl J Med. 2026;395:592.
    PubMed        
    
    

    
    Nat Rev Neurol

35. THOMPSON AJ, Lublin FD, Rechtman L, Quinn J, et al
    Towards a biologically informed description of multiple sclerosis disease course - a roadmap for transition.
    Nat Rev Neurol. 2026 Aug 3. doi: 10.1038/s41582-026-01249.
    PubMed         Abstract available
    
    

    
    Neurol Clin Pract

36. GILMARTIN CGS, Paskin T, Clarke MA, De Dios Perez B, et al
    A Faster Way to Diagnose Multiple Sclerosis: The Central Vein Sign in Routine Clinical Practice.
    Neurol Clin Pract. 2026;16:e200647.
    PubMed         Abstract available
    
    

    
    Neurology

37. KWON S, Kim BS, Han K, Heo NJ, et al
    Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis: A Nationwide Cohort Study in South Korea.
    Neurology. 2026;107:e218377.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum